Y-90 Selective Internal Radiation Therapy for Potentially Resectable Hepatocellular Carcinoma: a Prospective, Single Arm Trial
This study is conducted to evaluate the efficacy and safety of Y-90 selective internal radiation therapy (SIRT) in patients with potentially resectable hepatocellular carcinoma (HCC).
• HCC with diagnosis confirmed pathologically or clinically
• No pervious treatment for HCC
• At least one measurable intrahepatic target lesion
• Potentially resectable HCC: tumor(s) confined to the left/right hemiliver, with/without invasion to the unilateral branch of the portal vein and/or hepatic vein
• Disease amenable to SIRT (after evaluation)
• Child-Pugh Class A or without cirrhosis
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
• Patients with active hepatitis B are allowed, but they need to receive antiviral treatment to achieve a HBV DNA\<10\^3 IU/mL
• Patients with hepatitis C need to finish the anti-HCV treatment
• Adequate organ and bone marrow function; the blood biochemical examination: platelet count ≥75×10\^9/L, white blood cell count \>3.0×10\^9/L, absolute value of neutrophils \>1.5×10\^9/L, hemoglobin ≥85 g/L, ASL and AST≤5×ULN, creatinine≤1.5×ULN, INR\<1.5 or PT/APTT normal range
• Life expectancy of at least 6 months